Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production
Helen Chen, … , Lawrence T. Reiter, Patrick Ryan Potts
Helen Chen, … , Lawrence T. Reiter, Patrick Ryan Potts
Published September 3, 2020
Citation Information: JCI Insight. 2020;5(17):e138576. https://doi.org/10.1172/jci.insight.138576.
View: Text | PDF
Research Article Cell biology Neuroscience

Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production

  • Text
  • PDF
Abstract

Prader-Willi syndrome (PWS) is a developmental disorder caused by loss of maternally imprinted genes on 15q11-q13, including melanoma antigen gene family member L2 (MAGEL2). The clinical phenotypes of PWS suggest impaired hypothalamic neuroendocrine function; however, the exact cellular defects are unknown. Here, we report deficits in secretory granule (SG) abundance and bioactive neuropeptide production upon loss of MAGEL2 in humans and mice. Unbiased proteomic analysis of Magel2pΔ/m+ mice revealed a reduction in components of SG in the hypothalamus that was confirmed in 2 PWS patient–derived neuronal cell models. Mechanistically, we show that proper endosomal trafficking by the MAGEL2-regulated WASH complex is required to prevent aberrant lysosomal degradation of SG proteins and reduction of mature SG abundance. Importantly, loss of MAGEL2 in mice, NGN2-induced neurons, and human patients led to reduced neuropeptide production. Thus, MAGEL2 plays an important role in hypothalamic neuroendocrine function, and cellular defects in this pathway may contribute to PWS disease etiology. Moreover, these findings suggest unanticipated approaches for therapeutic intervention.

Authors

Helen Chen, A. Kaitlyn Victor, Jonathon Klein, Klementina Fon Tacer, Derek J.C. Tai, Celine de Esch, Alexander Nuttle, Jamshid Temirov, Lisa C. Burnett, Michael Rosenbaum, Yiying Zhang, Li Ding, James J. Moresco, Jolene K. Diedrich, John R. Yates III, Heather S. Tillman, Rudolph L. Leibel, Michael E. Talkowski, Daniel D. Billadeau, Lawrence T. Reiter, Patrick Ryan Potts

×

Figure 8

Neuropeptide production and release are impaired in Magel2pΔ/m+ mice and human PWS iN.

Options: View larger image (or click on image) Download as PowerPoint
Neuropeptide production and release are impaired in Magel2pΔ/m+ mice and...
(A) Peptide abundance of indicated neuropeptides in 8-week-old Magel2+/+ and Magel2pΔ/m+ mouse hypothalamuses. Each data point represents 1 animal, plotted as mean ± SD (n = 5 per genotype) and indicated P values as analyzed by unpaired, 2-tailed t test with Bonferroni’s correction. (B–F) Reduced levels of plasma OXT (B), AVP (C), SST (D), GnRH (E), and α-MSH (F) in 14-week-old Magel2pΔ/m+ mice, measured by ELISA. Each data point represents 1 animal, plotted as mean ± SD (n > 5 per genotype), and analyzed by unpaired, 2-tailed t test. (G) ELISA analysis of oxytocin levels in human iN media, at basal level and after KCl (50 mM, 30 minutes) stimulation. Each data point represents 1 induction experiment, plotted as mean ± SD (n = 3), and analyzed by 1-way ANOVA. (H) Transcript levels of various neuropeptides between 8-week-old Magel2pΔ/m+ and Magel2+/+ mouse hypothalamuses. Each data point represents 1 animal, plotted as mean ± SD (n = 3 per genotype) and analyzed by unpaired, 2-tailed t test. (I) Transcript levels of various neuropeptides between control and PWS iN at 14 days postinduction. Each data point represents 1 induction experiment (n = 2), plotted as mean ± SD and analyzed by 1-way ANOVA. (J) Reduced levels of plasma CHGB in PWS patients after 12 hours of fasting, measured by ELISA. Each data point is a unique individual, plotted as mean ± SD and analyzed by Mann-Whitney U test. *P < 0.05, ***P < 0.001, and ****P < 0.001.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts